Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Pluristem Therapeutics (Nasdaq: PSTI) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Pluristem's business and see what CAPS investors are saying about the stock right now.

Pluristem facts

Headquarters (founded) Haifa, Israel (2001)
Market Cap $212.9 million
Industry Biotechnology
Trailing-12-Month Revenue $615.0 thousand
Management Chairman/CEO Zami Aberman
CFO Yaky Yanay
Return on Equity (average, past 3 years) (109%)
Cash/Debt $39.5 million / $0
Competitors Aastrom Biosciences
Advanced Cell Technology
Osiris Therapeutics

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 94% of the 18 All-Star members who have rated Pluristem believe the stock will underperform the S&P 500 going forward.

Just last month, one of those Fools, zzlangerhans, tapped Pluristem's recent price surge as highly unsustainable:

You can't sell your snake oil in the USA until [the FDA has] approved it. In order to get something past them, you have to demonstrate a benefit that outweighs the risk in large, randomized clinical trials. That's an area where Pluristem has actually made very little progress in recent months, despite their exciting announcement of the selection of a contract company for an upcoming phase II trial. No word on when that trial will actually begin, and likewise for other promised late stage trials. ... Is the move over? Don't really know. But eventually the money will have been made by the insiders and manipulators and the retail traders will ride the wave back down to baseline.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found a growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.